NewsRoom Articles - Page 16 of 154 - PsychedelicNewsWire (PNW)

FridayDec 22, 2023 2:50 pm

Absence of Social Support, Stressful Environments Linked to Adverse Outcomes for Psychedelics Users

Scientists from the Imperial College London’s Center for Psychedelic Research have published a study indicating that psychedelics are linked to adverse outcomes when users are in stressful environments and have limited social support. Published in the “Scientific Reports” journal, the study delved into the potential negative psychological effects associated with psychedelic drug use. The study found that in the absence of social support, psychedelic users are at risk of experiencing psychological issues such as panic and persistent anxiety, especially if they are in particularly stressful environments. With the recent resurgence in psychedelic research contributing to significant hype around the mental-health…

ThursdayDec 21, 2023 4:23 pm

Five Key 2023 Clinical Studies That Suggest Optimal Psilocybin Dosing

Research in the psychedelic field has flourished in 2023, with the latest studies showing that psilocybin may be legalized in a couple of years. Below, we look at key clinical studies that suggest optimal psilocybin dosing for mental health conditions such as depression. COMP360 Psilocybin therapy trial COMP360 is a synthetic psilocybin formulation developed by Compass Pathways PLC (NASDAQ: CMPS). The company, in partnership with Sunstone Therapies, recently carried out a phase 2 trial involving the use of their COMP360 psilocybin therapy on cancer patients who suffered from major depressive disorder. The researchers determined that with a single 25mg dose…

WednesdayDec 20, 2023 3:25 pm

Kentucky Mulls Funding Ibogaine Research Against Opioid Addiction

Some Kentucky advocates are considering the idea of exploring ibogaine, a relatively unknown psychedelic drug, as a potential treatment for opioid addiction. The Kentucky Opioid Abatement Advisory Committee is thinking of funding ibogaine research as part of efforts to combat the spiraling opioid epidemic and save countless lives. America has been in the grip of an opioid epidemic and has lost hundreds of thousands of people to opioid overdoses over the past two decades. Opioids have been the main treatment option for chronic pain conditions for several decades due to their incredible pain-relieving capabilities. However, they have an extremely high…

TuesdayDec 19, 2023 9:00 am

DEA Renews Efforts to Ban Psychedelics Despite Backlash in 2022

Last week, the Drug Enforcement Administration (DEA) suggested that DOC and DOI be classified under Schedule I of the Controlled Substances Act in its latest notice. DOC (2,5-dimethoxy-4-chloroamphetamine) and DOI (2,5-dimethoxy-4-iodoamphetamine) are both psychedelic drugs of the amphetamine and phenethylamine chemical classes. In its latest notice, the DEA stated that the medical and scientific basis for suggesting the ban was that these hallucinogens had no known medical value and a high potential for abuse. This is despite the fact that the agency possesses no evidence demonstrating a high abuse potential or directly linking the compounds to severe health events. In…

MondayDec 18, 2023 10:59 am

Startup Secures US Patents for Synthetic Psychedelics

Terran Biosciences, a drug developer based in New York, announced recently that it had obtained patent approval for its psychedelic drugs from the U.S. Patent and Trademark Office. The drugs, which have been designed to treat neurological and psychiatric disorders, are based on psilocybin, namely psilocybin edisylate and psilocybin HCI. Terran Biosciences describes the drugs as the world’s first new polymorphs and salts of psilocybin, noting that the patents will include techniques for treating the aforementioned disorders. Dr. Sam Clark, Terran CEO and founder, stated that the company was approaching its goal of providing patients with accessible and affordable psilocybin…

FridayDec 15, 2023 11:13 am

FDA Assessing MAPS’ Application for MDMA as Treatment for PTSD

The MAPS Public Benefit Corporation (MAPS PBC), a psychedelics-focused, drug-development company, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA). MAPS PBC is asking the FDA to approve the use of MDMA (ecstasy, molly) as a prescription medication for treating post-traumatic stress disorder (PTSD). The company is requesting that the federal agency provide an expedited review of the psychedelic as the FDA had already designated it as a breakthrough therapy. The FDA granted breakthrough therapy designation for MDMA in PTSD treatment in 2017 and reached an agreement with MAPS to design two MDMA phase…

ThursdayDec 14, 2023 11:56 am

JAMA Article Suggests Psychedelics Industry Likely to Clash with FDA

Several states in the United States have already approved the use of psychedelics, even before the U.S. Food and Drug Administration (FDA) has concluded trials and drug approvals. For instance, the state of Oregon legalized the nontherapeutic use of psilocybin and established a program for supervised use following approval of Measure 109 by voters. Soon after this, voters in the state of Colorado approved Proposition 122, which will allow psychedelic businesses to launch come 2025. Other states planning to approve similar measures in 2024 include California, New York, Illinois, Vermont and Massachusetts. At the moment, the FDA is reviewing psychedelics…

WednesdayDec 13, 2023 12:05 pm

California Campaigners Submit Final Text of 2024 Psychedelics Legalization Ballot Measure

The campaign behind a ballot measure in California to legalize psychedelic substances has presented a final amended resolution to officials in the state. Various changes have been made to the initiative following a public comment period that concluded in November. For instance, the changes expanded the types of businesses that could operate and also required that larger psychedelics businesses acquire peace agreements with labor unions. In addition, under the revised measure, adults would be permitted to legally use, possess and grow psychedelics such as LSD, psilocybin, DMT, MDMA, mescaline and ibogaine. However, one would require a recommendation from a physician…

TuesdayDec 12, 2023 9:00 am

Longevity Movement Looks to Tap Benefits of Psychedelics

America’s longevity movement, a growing community of people committed to reversing aging, is the latest group to take notice of psychedelics. A recent surge of psychedelic-related studies has revealed that hallucinogenic drugs such as LSD, ayahuasca and psilocybin (magic mushrooms) have the potential to treat several mental disorders. These initial studies have found that psychedelics can be especially effective when paired with traditional talk therapy, offering long-term relief against hard-to-treat conditions, including post-traumatic stress disorder (PTSD), eating disorders and treatment-resistant depression, with few side effects and at minimal doses. The findings have been so promising that researchers and mental-health experts…

MondayDec 11, 2023 12:56 pm

AMA Study Shows Safety, Efficacy of Psilocybin in Treating Bipolar Depression

A new clinical study from the American Medical Association (AMA) has indicated that psilocybin-assisted psychotherapy may be safe and effective in the treatment of bipolar II disorder depressive episodes. The nonrandomized controlled study was conducted at Baltimore’s Sheppard Pratt Hospital and involved 15 patients diagnosed with treatment-resistant BDII depression with lengthy depressive episodes. After receiving a single psilocybin dose followed by seven psychotherapy sessions, researchers say study participants “displayed strong and persistent antidepressant effects” with no increase in mood instability of suicidality. Patients with bipolar II disorder (BDII) received a 25-milligram dose of psilocybin and had seven sessions with therapists…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000